




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 39/395, 47/00		(11) International Publication Number: WO 89/11297
A1		(43) International Publication Date: 30 November 1989 (30.11.89)
(21) International Application Number: PCT/US89/02252 (22) International Filing Date: 24 May 1989 (24.05.89) (30) Priority data: 199,931 27 May 1988 (27.05.88) US (71) Applicant: CENTOCOR, INC. [US/US]; 244 Great Valley Parkway, Malvern, PA 19355 (US). (72) Inventors: PHILLIPS, Christopher, P. ; P.O. Box 65, Brandamore, PA 19316 (US). MATTIS, Jeffrey, A. ; 1220 Upton Circle, West Chester, PA 19380 (US). (74) Agents: DeCONTI, Giulio, A., Jr. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: FREEZE-DRIED FORMULATION FOR ANTIBODY PRODUCTS

ACTIVITY ASSAYC1 CELL FREE ACTIVITY ASSAY
52 DAYS AT 4, 22 AND 40C

(57) Abstract

A lyophilized formulation for the stabilization of mouse monoclonal antibodies intended for parenteral administration containing a low pH buffer, a stabilizing carbohydrate and monoclonal antibodies. Lyophilization results in a dried, stable product which is readily reconstituted to provide an injectable, particle-free antibody solution which can be administered without prior filtration.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

FREEZE-DRIED FORMULATION FOR ANTIBODY PRODUCTSBackground of the Invention

A major challenge that exists in the field of new protein drugs is in the formulation of protein solution products that maintain both protein solubility and biological activity. It is well known that purified monoclonal antibodies, for example, tend to precipitate from the solution when subjected to physical or chemical stress, or over time. Many protein preparations are unstable in solution, and the instability is manifested in the formation of insoluble particles in the solution. The formation of these particles is often increased by physical stress, such as storage for prolonged periods and shipping; and by chemical stress such as dilution or mixing with an additive. Such particulates are not acceptable in terms of visual appearance of the product or USP specifications, and cause much difficulty in the development of suitable liquid formulations of monoclonal antibodies intended for intravenous injection.

The precipitation of proteins from aqueous solutions is a well known phenomenon. Immunoglobulins, in particular, possess characteristics that tend to generate particles in solution, so that an immunoglobulin solution generally must be filtered before used for intravenous injection.

-2-

Conditions which lead to increased precipitation of immunoglobulins include long term storage, filling vials with automated equipment and shipping.

05 Various methods for stabilizing protein preparations have been used, including increasing the concentration of protein in solution or adding an additional protein, such as human serum albumin. However, such preparations may not be acceptable for therapeutic purposes.

10 Various carbohydrates are known to stabilize and/or enhance the stability of certain biologically active protein preparations. For example, U.S. Patent 4,186,192 to Lundblad et al. discloses the use of maltose to increase the stability of an
15 immune serum globulin preparation for intramuscular or intravenous administration. T. Arakawa and S. N. Timasheff describe the stabilization of protein structure by lactose and glucose in Biochemistry, 21:6536-6544 (1982). Gazzei et al. describe the
20 addition of saccharose to a formulation of immunoglobulins in European Patent Application 221,505.

Maltose has been added to protein solutions to enhance stability of the proteins in solutions and to impart isotonicity to a solution. Maltose has
25 many advantages, including availability in pure form and stability in aqueous solutions. Preparations containing maltose can be autoclaved without browning of the solution. Maltose in small quantities is practically physiologically inert. When adminis-
30 tered parenterally, it is gradually

-3-

converted to glucose by the enzyme maltase; however, the conversion to glucose is gradual and frequently undetectable when serum glucose is measured. Therefore, there is no detectable increase in circulating
05 insulin levels. In U.S. Patent 4,449,073, Tenold discloses the use of maltose in a preparation of immune serum globulin to impart physiologically acceptable isotonicity to the preparation. Tenold specifies 10% weight to volume maltose for this
10 purpose. Lundblad et al., report in U.S. Patent 4,186,192 that the stability of a solution of immune serum globulin is increased by adding maltose in a concentration between 5 and 18% by weight. Fernandes et al. describes a preparation of
15 intravenous gamma globulin stabilized with maltose to minimize precipitation and improve in vitro shelf stability in Vox Sang, 39:101-112 (1980).

One approach used to circumvent this problem is the development of lyophilized drug forms.
20 Lyophilization is the freeze-drying of biological material. Generally, the material is first frozen and then placed in a high vacuum so that the water (in the form of ice) sublimates into the vacuum and the non-water components are left behind in an
25 undamaged state. The resulting product is a cake-like substance which can then be stored for long periods of time without degradation. The powder is reconstituted at the time of use to a liquid product by the addition of water, saline or
30 other diluent. The reconstituted solution is then ready to be administered to the subject.

-4-

Summary of the Invention

This invention relates to a lyophilized composition containing a monoclonal antibody, a buffer and maltose, intended for parenteral administration.

- 05 The invention further relates to a method for preparing the lyophilized product. The lyophilized composition of the invention preserves the biological activity of the monoclonal antibody, and minimizes formation of particulates caused by
- 10 precipitation or aggregation of the monoclonal antibody when the freeze-dried product is reconstituted. The reconstituted solutions are particle-free, show no loss of biological activity and can be administered without prior filtration.

15 Brief Description of the Drawings

Figure 1 shows the gel filtration HPLC results comparing lyophilized and liquid samples of IgG exposed to a range of stress temperatures for 95 days.

- 20 Figure 2 shows the results of an immuno-reactivity assay comparing binding ability of both lyophilized and 10% maltose liquid samples of IgG which have been exposed to a range of stress temperatures for 95 days.

-5-

Figure 3 shows the HPLC gel filtration results of lyophilized 2% maltose samples exposed to a range of stress temperatures for 52 days.

Figure 4 shows the results of an immuno-
05 reactivity assay for lyophilized samples of 2% maltose exposed to a range of stress temperatures for 52 days.

Detailed Description of the Invention

The formulation comprises a lyophilized
10 composition containing a low pH buffer, a carbohydrate component and an antibody or antibody fragment. The liquid composition is prepared, then lyophilized to form a cake-like product. The lyophilized product can be stored for prolonged
15 periods of time, and at elevated temperatures, without loss of biological activity, and is readily

-6-

reconstituted into a particle-free solution by the addition of water, saline or other diluent.

05 Lyophilization is a freeze drying process which is often used in the preparation of pharmaceutical products to preserve their biological activity. The process generally involves drying a previously frozen sample in a vacuum to remove the ice, leaving the non-water components intact, in the form of a powdery or cake-like substance. The dried product is then be reconstituted at the time of use by the addition of water, saline solution, buffer or other appropriate liquid to produce a solution of the antibody. The advantage of lyophilization is that the biological activity of the antibody is pre-
15 served, and solution stress caused by exposure to varying temperatures, shear forces and shipping is avoided. The lyophilized product is readily reconstituted and is particle free, so it can be administered intravenously without prior filtration.

20 One embodiment of the present formulation is a solution containing a buffer, maltose and a murine monoclonal antibody or antibody fragments, such as immunoglobulin G (IgG), which is lyophilized to form a cake-like product.

25 All subclasses of immunoglobulin G can be used, e.g. immunoglobulin G₁, G₂, G_{2a}, G_{2b} and G₃. The antibody or antibody fragment can be derivatized so that it binds with a radiometal, such as Technetium-99m or Indium-111. The antibody can be
30 derivatized either by changing its native state so that a radiometal can be bound directly to the

-7-

protein, or with a chelating agent such as diethylenetriaminepentaacetic acid (DTPA). The derivatized antibody can be used as a radio pharmaceutical due to the derivatized antibody's ability to bind a radioactive heavy metal (e.g. Indium-111 or Technetium-99m) to the antibody protein, forming a protein-radiometal complex, or, in the case of a chelating agent, a protein-chelate-radiometal complex. The radiolabeled antibody can then be used in immunoscintigraphy, for example, for in vivo diagnostic imaging of tumors or disease sites. IgG labeled with a radiation source, such as Tc-99m, can be administered to a subject. The labeled antibody localizes at the site defined by anti-IgG, and the site can then be scanned with a gamma camera, and an image obtained.

A preferred embodiment of the invention is a formulation containing a buffer having a low pH (between about 3 to 6), maltose and IgG. Preferred buffers include sodium acetate, phosphate and citrate buffers. A more preferred embodiment is a formulation containing about 5-100 mM sodium acetate, having a pH between about 3-6, 2-10% maltose and 1 to 25 mg/ml IgG.

The liquid formulation can be lyophilized using appropriate drying parameters. The following drying parameters are preferred: a primary drying phase

-8-

temperature of about -40°C to -42°C and pressure between about 50 mTorr to about 80 mTorr; and a secondary drying phase at ambient temperature, and pressure between about 50 mTorr to 80 mTorr.

05 Maltose, which is used to stabilize the antibody solutions, is described in detail in, for example, the Merck Index, 10th edition, Merck and Co., Inc. Rohway, NJ (1983). Maltose is a dissaccharide (4-O-
10 -D-glucopyranosyl-D-glucopyranose) having the general formula $C_{12}H_{22}O_{11}$, which has been established as useful for stabilizing immunoglobulin solutions. (See U.S. Patent 4,499,073 to Tenold and U.S. Patent 4,186,192 to Lundblad, et al.). Maltose
15 is not metabolized by humans when administered intravenously, and is excreted as maltose with no apparent elevation in blood glucose levels or release of insulin.

The lyophilized product is redissolved at the time of use in a diluent (e.g., sterile water or
20 saline) and yields a particle-free solution. Reconstitution is complete in about two minutes. The reconstituted antibody solution is particle-free even after prolonged storage of the lyophilized cake at 37°C. The reconstituted solution is then
25 administered parenterally, preferably intravenously, to the subject.

The invention is further illustrated by the following exemplification:

-9-

ExemplificationExample 1. Preparation of a Stabilized Lyophilized Formulation of Immunoglobulin G.

05 Desalting of IgG from 0.9% Saline Into a
 solution of 10mM Sodium Acetate (pH 4.5)
 containing 10% Maltose

 A 3.3 L Sephadex G-25 medium column (Pharmacia)
 packed in 0.1 M sodium hydroxide was equilibrated
 with a solution of 10 mM sodium acetate (pH 4.5) and
10 10% w/v maltose before applying the protein. 500 ml
 of IgG (Centocor, Inc., Malvern, PA) at a
 concentration of 11.54 mg/ml (5.693g total) was
 applied to the column at a flow rate of 550 ml/hr.
 The protein peak was collected and concentrated to
15 10 mg/ml via stirred cell with YM30-membrane
 (Amiccn).

 The entire lot was split in half, and one part
 was maintained in the liquid state, and the other
 dedicated for freeze-drying. Each part consisted of
20 25 vials that were subjected to temperature stress
 testing upon the completion of the lyophilization
 process.

Lyophilization of IgG Formulation

25 Twenty milliliter vials (West Co.) were filled
 with 10 ml of the formulation and placed in the
 freeze dryer (FTS). Since freeze-drying was not
 under sterile conditions, 100 ul of 10% sodium azide
 was added to the lyophilized samples as a bacterio-
 static agent.

30 Placebo vials, filled with the identical buffer
 and maltose but lacking antibody, were also placed

-10-

in the lyophilizer. The degree of supercooling of the formulation was -6°C and formed a uniform matrix. The product was initially frozen to -45°C. After freezing to this temperature, the shelf surface temperature was adjusted to between -40 to -42°C, with the pressure reduced to 50 mTorr to initiate the primary drying phase.

Once the primary drying phase was completed, the shelf surface temperature was raised to +20°C to initiate the secondary drying phase. The composition of the gases in the chamber were monitored via residual gas mass spectrum until nitrogen had replaced water vapor as the species in the chamber. The secondary drying phase required about 8 hours.

After reaching this point, the chamber was back-filled with dry nitrogen and the vials were stoppered.

The procedure yielded 25 vials of lyophilized product at 10 ml/vial, 10.0 mg/ml.

Temperature Stress Study

Representative vials from both the liquid and freeze-dried formulations were exposed to temperatures of 4, 22, 37 and 50°C.

After 95 days under such conditions, one vial from each formulation at each temperature was removed for analysis. The lyophilized product was reconstituted with 10 ml of water. The reconstitution times are shown in Table 1 below.

-11-

Table 1Reconstitution Times (Lyophilized Product)

		<u>Reconstitution</u>
		<u>Time (Minutes)</u>
05	<u>Sample</u>	
	t_o sample	1

	<u>95 day samples</u>	
	4°C	2
	22°C	2
	37°C	2.5
10	50°C	2

Each vial was then visually examined for particulates. The vials were examined by holding the vial directly in front of a black background and lighting the vial from below. Visual comparison of reconstituted lyophilized product to liquid samples demonstrated the superiority of the lyophilized product. The liquid samples all contained particulation of some degree, whereas the reconstituted samples were clear and free of particulates. The liquid samples also showed increased yellowing as the temperature increased. The results of the visual examination are shown in Table 2.

-12-

Table 2Visual Examination

	<u>T°C</u>	<u>Formulation</u>	<u>Observation</u>
05	4	liquid	small flakes
	22	liquid	small flakes and fine precipitation
	37	liquid	fine particulates, slightly yellow liquid
10	50	liquid	moderate particulation, yellow liquid
	4	lyophilized	clear
	22	lyophilized	clear
	37	lyophilized	clear
	50	lyophilized	clear

15 Liquidborne Particle Analysis

The vials were then analyzed in a liquidborne particle analyzer (Climet). The samples were analyzed for particles ranging in size from 5 to 50 microns. Subvisible liquidborn particle analysis

20 showed some superiority of the reconstituted lyophilized samples over the liquid samples. The results are shown in Table 3.

-13-

Table 3

Subvisible Liquidborne Particle Analysis
(particles per milliliter)

			<u>Differential</u>					<u>Total</u>						
	T°C	Formulation	5u	10u	20u	25u	30u	50u	5u	10u	20u	25u	30u	50u
05	4	Liquid	188	92	18	12	50	172	932	344	--242	234	222	172
	22	Liquid	182	50	6	2	6	0	246	64	--14	8	6	0
	37	Liquid	282	102	12	4	10	2	412	130	28	16	12	2
	50	Liquid	204	92	14	6	10	4	330	126	--34	20	14	4
10	4	Lyophilized	230	64	4	2	0	0	300	70	6	2	0	0
	22	Lyophilized	236	42	4	2	2	0	256	50	8	4	2	0
	37	Lyophilized	194	28	4	2	2	0	230	36	8	4	2	0
	50	Lyophilized	550	82	14	10	8	0	664	114	32	18	8	0

HPLC Gel Filtration Chromatography

15 The samples were subjected to HPLC gel
 filtration chromatography. An HPLC unit (DuPont
 Zorbarx GF-250 HPLC) was equilibrated with .2 M
 sodium phosphate buffer (pH 6.8) at a flow rate of 1
 ml/min. Absorbance wavelength was set at 214 nm.
 20 Undiluted samples were injected and analyzed. The
 results showed that both liquid and reconstituted
 samples were relatively stable under the 4°C and
 22°C stress conditions. At 37°C and 50°C, the
 liquid samples showed a measurable increase in dimer
 25 concentration generating 10.48% dimer at 37°C and
 90.05% dimer at 50°C. The reconstituted samples
 show no increase in dimer levels at 37°C and 50°C.
 The results are shown in Figure 1.

-14-

Immunoreactivity Assay

An assay was performed on the samples to determine the relative immunoreactivity of the IgG in the samples. The activity analysis showed that antibody activity was maintained in both liquid and lyophilized samples. The results are shown in Figure 2.

The procedure used for determining antibody immunoreactivity is as follows:

In a polyvinylchloride (PVC) plate labeled "Antigen", 50 ul of diluted antigen was dispensed into each of the 96 wells. The plate was placed uncovered at 37°C to air dry for four hours. After all the solution had evaporated from the wells, each well was washed twice with 100 ul of phosphate buffered saline (PBS). To each well, 200 ul of 5% bovine serum albumin (BSA) in PBS was dispensed, and allowed to incubate covered for 2 hours at room temperature.

In a separate PVC plate labeled "Antibody", 75 ul of 10% BSA in PBS was dispensed into wells in rows 2 through 12. 100 ul of the reconstituted lyophilized samples and standard antibody solutions that had been pre-diluted to 400 micrograms/ml were dispensed to wells in row 1. With a pipetting device, 25 ul was removed from row 1, dispensed to row 2 and mixed. This dispensing was repeated for the wells in rows 3 through 11. The final 25 ul increment was discarded. Row 12 was the 100% binding row.

-15-

PVC plates labeled "Antigen" were washed twice with 200 ul of PBS. Using new pipette tips each time, 50ul of the prediluted antibody was transferred from the PVC plate labeled "Antibody" to corresponding wells on the "Antigen" plate. To each well on the "Antigen" plate containing 50 ul of prediluted antibody, 20 nanograms of ¹²⁵I labeled antibody in 50 ul of 1% BSA in PBS was added. The plate was covered and incubated at 4°C for 20 hours. After 20 hours at 4°C, the excess radiolabel was washed from the plate with three washes of PBS, and counted in a gamma counter.

The data were analyzed by averaging duplicate counts. Counts per minute (cpm) versus the negative log of the cold antibody were plotted. From row 12 of each antibody dilution series, the number of cpm found, which represents 100% of binding, was calculated. This number was divided by two to obtain the 50% maximal binding value. The 50% maximal binding value for each antibody dilution series was compared to the point on the curve for each antibody titration representing the cpm of the 50% maximal point. The protein concentration was determined from this point.

25 SDS:PAGE Chromatography

The samples were subjected to SDS:PAGE chromatography to determine molecular integrity of the IgG after stressing at various temperatures. Non-reduced samples were prepared in a microfuge

-16-

tube. Protein sample, PBS, and SDS and coomassie stock were mixed to obtain a protein concentration of 2mg/ml. Fifty microliters (50 ul) of the protein solution was reduced by adding 5 ul of β -mercaptoethanol. The samples in tubes were exposed to boiling water for 2 minutes. Using a 1 ul applicator comb, each prepared sample was applied to the gel (Pharmacia Phast Gel SDS Page Gels (8-25%)). The gel was run according to the manufacturers instructions.

SDS:PAGE chromatography demonstrated the molecular integrity of the lyophilization material throughout the range of stress temperatures. The liquid formulation maintained its structure at 4°C and 22°C, but begins to show increasing fragmentation at 37°C and 50°C.

Native PAGE Chromatography

The samples were tested using Native PAGE chromatography. The samples were diluted with PBS (phosphate buffered saline), and applied to Native Page Gel (Pharmacia Phast Gel Native Page Gel 7.5% and 12.5% homogeneous). The gels were run, stained and preserved according to the manufacturer's instructions. Native PAGE results showed some alterations in the proteins exposed to different temperatures, for both reconstituted lyophilized samples and liquid samples. The proteins in the liquid samples become more negatively charged at higher temperatures. Increases in negativity were observable with liquid samples stored at 22°C and

-17-

37°C, with no protein entering the gel at 50°C indicating extensive protein denaturation. The reconstituted lyophilized samples were observable in the gel throughout the temperature range, and the
05 lyophilized 50°C sample is less negative than the liquid 37°C sample. This phenomenon was consistent in both the 7.5% and 12.5% homogeneous gels, with the 12.5% gel appearing as more well-defined bands.

Isoelectric Focusing

10 Isoelectric focusing was conducted to determine any changes in the protein isoelectric point (pI) between the liquid and lyophilized samples. Samples were diluted with PBS and applied to an isoelectric focusing gel (Pharmacia Phast Gel pH 3-9 Isoelectric
15 Focusing Gel). The gel was run, fixed, stained and destained according to manufacturer's instructions. The results showed no alteration in the pI of the protein at any of the stress temperatures for the lyophilized product. The liquid samples
20 demonstrated no alteration at 4°C and 22°C, but showed considerable movement toward the lower pH range at 37°C, and denaturation at 50°C.

Residual Moisture Analysis

Residual moisture analysis was performed on
25 placebo lyophilized samples to determine the residual moisture attributable to the solution

-18-

without protein. Placebo vials contained a solution of 10 mM sodium acetate (pH 4.5), and 10% maltose. The placebo vials were lyophilized along with the vials containing antibody under the same conditions.

05 For the residual moisture analysis, the contents of placebo vials were removed into a dry pre-tared weigh boat (VWR Scientific) in a glove bag which had been previously purged with dry, inert gas. The sample was weighed to obtain an initial weight of

10 the placebo material. The weigh boat with the placebo material was then placed in a vacuum oven (VWR Scientific) at 60°C, and pressure in the vacuum oven was reduced for 24 hours. The weigh boats were then removed from the oven into a glove bag purged

15 with dry nitrogen gas, and allowed to equilibrate to room temperature. The samples were then reweighed. The sequence was repeated until the samples were brought to constant weight (there were no more reductions in weight). The final constant weight

20 was divided by the original weight to calculate the percent residual moisture. The results are shown in Table 4.

Table 4
Residual Moisture Analysis (lyophilized)

Vial#	Weigh Boat	Weigh Boat	Placebo		%	
	Tare (g)	+ Placebo	Placebo	After Drying	Loss In Drying	Residual Moisture
1	1.57387	2.41015	0.83628	0.81698	0.01930	2.31
2	1.54695	2.42704	0.88009	0.86034	0.01975	2.24
30 3	1.58552	2.44362	0.85810	0.83867	0.01943	2.26

AVERAGE VALUE = 2.27%

-19-

Example 2. Preparation of a Lower Maltose
Lyophilized Formulation for IgG

05 Solutions of immunoglobulin G were prepared and
tested according to the procedures set out in
Example 1, but reducing the amount of maltose in the
formulation from 10% to 2%. This formulation
consisted of 10mM sodium acetate (pH 4.5), 2% w/v
maltose and IgG.

Lyophilization

10 Twenty milliliter vials were prepared and filled
with 10 ml of the reduced-maltose formulation and
placed in the freeze dryer. Placebo vials, filled
with the identical solution of buffer and maltose,
but lacking antibody, were also placed in the freeze
15 dryer. Lyophilization was carried out as described
in Example 1.

Temperature stress testing of the lyophilized
product and the placebo vials was done by storing
the test samples at 4, 22 and 40°C for 52 days.
20 Some of the lyophilized samples were then
reconstituted with 10 ml of water. The
reconstitution times are shown in Table 5.

-20-

Table 5Reconstitution Times (Lyophilized Product)

<u>Sample</u>	<u>Reconstitution Time (Minutes)</u>
05	t_o
	0.5
<hr/>	
<u>52 day samples</u>	
4°C	0.67
22°C	0.75
40°C	0.83
10	Visual examination of the vials for particulates was then performed. Visual examination showed no visible particulates in the reconstituted lyophilized samples. The results are shown in Table 6.

Table 6

15	<u>Visual Examination</u>		
	<u>T°C</u>	<u>Formulation</u>	<u>Observation</u>
	4	lyophilized	Clear
	22	lyophilized	Clear
20	40	lyophilized	Clear

-21-

Liquidborne Particle Analysis

Liquidborne particle analysis showed that all samples were within USP specifications for 10 and 25 micron-sized particles. The results are shown in

05 Table 7.

Table 7Subvisible Liquidborne Particle Analysis (52 Days)

		DIFFERENTIAL						TOTAL					
T°C		5u	10u	20u	25u	30u	50u	5u	10u	20u	25u	30u	50u
10	4	313	54	2	2	0	0	376	58	4	2	0	0
	22	910	142	10	2	4	0	1068	158	16	6	4	0
	40	676	108	4	2	2	0	794	118	10	6	4	0

HPLC Gel Filtration Chromatography

Gel filtration results showed that the

15 reconstituted material stressed at 4°C and 22°C were identical with the starting material. At 40°C, however, some dimer formation was apparent (about 2.12%). The results are shown in Figure 3.

Immunoreactivity Assay

20 Immunoreactivity assay results indicate that all samples performed within specification for the

-22-

assay, and possessed activity comparable to the standard. The results are shown in Figure 4.

SDS:PAGE Chromatography

05 SDS-PAGE gels for all samples appeared the same when loaded at 2 mg/ml on the non-reduced and reduced gels. When samples were loaded at 1 mg/ml, some aggregated material was observed only in the 40°C sample.

Native Page Chromatography

10 Native:PAGE gels (both 7.5% and 12.5% homogenous) exhibited a slight alteration in surface charge in the 40°C stressed samples.

Isoelectric Focusing

15 Isoelectric focusing of the freeze dried samples showed no change in the banding patterns at any of the temperature conditions.

Residual Moisture

20 Residual moisture analysis performed on three of the placebo vials showed an average residual moisture value of 1.24%. The results are shown in Table 8.

-23-

Table 8RESIDUAL MOISTURE ANALYSIS

05	<u>VIAL #</u>	<u>WEIGH BOAT</u>	<u>WEIGH BOAT</u>	<u>PLACEBO</u>		<u>LOSS IN</u>	<u>% RESIDUAL</u>
		<u>TARE (g)</u>	<u>+PLACEBO</u>	<u>PLACEBO</u>	<u>AFTER</u> <u>DRYING</u>	<u>DRYING</u>	<u>MOISTURE</u>
	1	1.58839	1.77753	0.18914	0.18555	0.00359	1.90
	2	1.54959	1.74645	0.19686	0.19471	0.00215	1.09
	3	1.55476	1.71318	0.15482	0.15726	0.00116	0.73

AVERAGE VALUE = 1.24%

10 Equivalents

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein.

15 Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

-24-

Claims

- 05 1. A monoclonal antibody composition comprising a lyophilized formulation of a buffer, a monoclonal antibody or antibody fragments, and maltose.
2. A composition of Claim 1 wherein the monoclonal antibody is immunoglobulin G.
- 10 3. A composition of Claim 2 wherein the amount of immunoglobulin G is between about 1 to about 25 mg/ml.
4. A composition of claim 1 wherein the antibody fragments are derived from immunoglobulin G.
5. A composition of Claim 1 wherein the antibody or antibody fragments are radiolabeled.
- 15 6. A composition of Claim 1 wherein the amount of maltose is between about 2 to about 10 percent by weight.
- 20 7. A composition of Claim 1 wherein the buffer is selected from the group consisting of sodium acetate, phosphate and citrate buffer.
8. A composition of Claim 7 wherein the buffer is sodium acetate having a pH between about 3.0 and 6.0.

-25-

9. An immunoglobulin G composition for parenteral administration comprising a lyophilized formulation of:
- (a) sodium acetate
 - (b) maltose
 - (c) immunoglobulin G or a fragment thereof.
10. A composition of Claim 9 wherein the amount of sodium acetate is between about 5 to about 10 mM and has a pH of between about 3-6.
11. A composition of Claim 9 wherein the amount of immunoglobulin G is between about 1 and about 25 mg/ml.
12. A composition of Claim 9 wherein the immunoglobulin G comprises immunoglobulin G_{2a}.
13. A composition of claim 9 wherein the immunoglobulin G fragment is radiolabeled.
14. A composition of Claim 9 wherein the amount of maltose is between about 2 to 10 percent by weight.
15. An improved immunoglobulin G composition containing sodium acetate, maltose and immunoglobulin G, wherein the improvement comprises lyophilizing the composition to form a lyophilized cake which may be reconstituted to yield an injectable solution of immunoglobulin G.

-26-

- 05 16. A method of preparing a monoclonal antibody formulation which comprises lyophilizing the formulation under conditions appropriate to form a lyophilized cake which is capable of being reconstituted into an injectable solution.
17. A method of Claim 16 wherein the formulation comprises sodium acetate, maltose and immunoglobulin G.
- 10 18. A method of Claim 17 wherein the formulation comprises:
- (a) about 5-10 mM sodium acetate having a pH of between about 3-6;
 - (b) about 2-10 percent by weight maltose; and
 - 15 (c) about 1-25 mg/ml immunoglobulin G.
19. A method of Claim 16 wherein the lyophilization conditions comprise:
- a primary drying phase wherein the temperature is between about -40°C to -42° C and the
 - 20 pressure is between about 50 mTorr - 80 mTorr; and a secondary drying phase wherein the temperature is ambient and the pressure is between about 50 mTorr - 80 mTorr.
- 25 20. A lyophilized cake comprising a stable composition of immunoglobulin G wherein the cake can be reconstituted to yield an immunoglobulin G

-27-

solution which has a particle count of less than about 150 particles of 10 micron size or greater per milliliter, and less than about 15 particles of 20 micron size or greater per milliliter.

- 05 21. A lyophilized cake of Claim 20 wherein the cake is reconstituted with water or saline solution.

1/5


HPLC Gel Filtration

FIG. 1




FIG. 1 (CONT.)

3/5

ACTIVITY ASSAY

COMPARISON OF LIQUID & FREEZE DRIED





FIG. 2

4/5


HPLC Gel Filtration (52 Days)

FIG. 3

ACTIVITY ASSAY

C1 CELL FREE ACTIVITY ASSAY
52 DAYS AT 4, 22 AND 40C




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/02252

I. CLASSIFICATION F SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 39/395, A 61 K 47/00											
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="width: 70%; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC⁴</td> <td style="padding: 5px;">A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁴	A 61 K					
Classification System	Classification Symbols										
IPC ⁴	A 61 K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border-right: 1px solid black; vertical-align: top; padding: 5px;">A</td> <td style="border-right: 1px solid black; vertical-align: top; padding: 5px;">EP, A, 0073371 (CUTTER LABORATORIES, INC.) 9 March 1983 & US, A, 4499073 (cited in the application) --</td> <td style="vertical-align: top; padding: 5px;"></td> </tr> <tr> <td style="border-right: 1px solid black; vertical-align: top; padding: 5px;">A</td> <td style="border-right: 1px solid black; vertical-align: top; padding: 5px;">US, A, 4186192 (LUNDBLAD et al.) 29 January 1980 cited in the application -----</td> <td style="vertical-align: top; padding: 5px;"></td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A, 0073371 (CUTTER LABORATORIES, INC.) 9 March 1983 & US, A, 4499073 (cited in the application) --		A	US, A, 4186192 (LUNDBLAD et al.) 29 January 1980 cited in the application -----	
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
A	EP, A, 0073371 (CUTTER LABORATORIES, INC.) 9 March 1983 & US, A, 4499073 (cited in the application) --										
A	US, A, 4186192 (LUNDBLAD et al.) 29 January 1980 cited in the application -----										
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">14th September 1989</td> <td style="border-bottom: 1px solid black; padding: 5px;">09. 10. 89</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px; text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px; text-align: right;"> T.K. WILLIS </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	14th September 1989	09. 10. 89	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	T.K. WILLIS	
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report										
14th September 1989	09. 10. 89										
International Searching Authority	Signature of Authorized Officer										
EUROPEAN PATENT OFFICE	T.K. WILLIS										

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8902252
SA 29239

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/10/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0073371	09-03-83	US-A- 4396608	02-08-83
		AU-B- 549204	16-01-86
		AU-A- 8726582	03-03-83
		CA-A- 1183084	26-02-85
		JP-A- 58043914	14-03-83
		US-A- 4499073	12-02-85
US-A- 4186192	29-01-80	AT-T- 866	15-05-82
		CA-A- 1117417	02-02-82
		EP-A, B 0012156	25-06-80
		JP-A- 55083711	24-06-80

EPF FORM 10079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82